Methotrexate levels and outcome in osteosarcoma Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Bone Neoplasms
  • Methotrexate
  • Osteosarcoma

abstract

  • The absence of a demonstrable correlation between peak MTX levels and histologic necrosis or EFS may suggest that most patients achieve therapeutic levels when MTX is given at a dose of 12 g/m(2). The significant degree of intra-patient variability in peak levels poses a dilemma for pharmacokinetic adjustment. Continued use of HD-MTX in all patients, rather than dose adapted therapy, may be justified.

publication date

  • June 15, 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/pbc.20314

PubMed ID

  • 15704189

Additional Document Info

start page

  • 638

end page

  • 42

volume

  • 44

number

  • 7